Noxopharm announced interim results from the dose-ranging component of the DARRT-1 study. Some of their key findings include combining Veyonda with low-dose radiotherapy applied to a single metastasis is able to produce an anti-cancer response in both the irradiated and non-irradiated lesions as evidenced by PSA response, pain reduction, and/or tumour measurements.
A study in JNCI Cancer Spectrum has identified a connection between prolonged time spent sitting while watching TV and an increased risk of colorectal cancer for younger Americans.
A study now underway aims to better incorporate patient feedback into clinical trials that help determine which new cancer treatments will be approved for use.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced unblinding of the phase III TITAN study evaluating Erleada (apalutamide) plus androgen deprivation therapy in the treatment of patients with metastatic castration-sensitive prostate cancer.
Findings from a pilot study at the University of Missouri School of Medicine show antioxidants such as alpha-lipoic acid may show promise working in tandem with temozolomide to further slow brain tumor growth in glioblastoma.
Finasteride, a generic hormone-blocking drug, was found to reduce the risk of prostate cancer by 25 percent in the landmark Prostate Cancer Prevention Trial.
The Addario Lung Cancer Medical Institute and researchers from the Dana-Farber Cancer Institute are launching a novel nationwide study to understand why treatment resistance develops in a specific group of lung cancer patients.
Note: The Cancer Letter has previously published information regarding this and can be found here.
Stephen Meltzer, a professor of medicine and oncology at the Johns Hopkins University School of Medicine, along with a team of researchers, clinicians and biomedical engineers have created a test—the “EsophaCap”—that uses specific genetic biomarkers to detect dangerous changes in the cells that line the inside of the esophagus. The paper was published in Clinical Cancer Research.
AbbVie announced an update on the phase III RESOLVE trial (PCYC-1137) of ibrutinib (Imbruvica) in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents in patients with metastatic pancreatic adenocarcinoma.
